Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?

@article{Barnes2017IsAT,
  title={Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?},
  author={Chad A. Barnes and Ashley N. Krepline and Mohammed Aldakkak and Callisia N. Clarke and Kathleen K Christians and Pierre-Alexandre Roger and Bryan C. Hunt and Paul S. Ritch and Ben George and William A. Hall and Beth A. Erickson and Douglas B. Evans and Susan Tsai},
  journal={Journal of Gastrointestinal Surgery},
  year={2017},
  volume={21},
  pages={1793-1803}
}
Among patients with localized pancreatic cancer (PC), the benefit of adjuvant therapy after neoadjuvant therapy and surgery is unknown. Patients with localized PC who completed all intended neoadjuvant therapy and surgery were categorized based on the receipt of adjuvant therapy and by pathologic lymph node status (LN−/LN+). Data was available from 234 consecutive patients, 121 (52%) with resectable and 113 (48%) with borderline resectable PC. Of the 234 patients, 92 (39%) were LN+ and 142 (61… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Approach to patients with pancreatic cancer without detectable metastases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2015
View 1 Excerpt

Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2014

Similar Papers

Loading similar papers…